Completed PHASE3 INTERVENTIONAL 2-arm NCT01091168

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Phase III Trial of IV Vinflunine Versus an Alkylating Agent in Patients With Metastatic Breast Cancer Previously Treated With or Resistant to an Anthracycline, a Taxane, an Antimetabolite, and a Vinca-alkaloid (Study L00070 IN 308 B0)

Sponsor: Pierre Fabre Medicament

Conditions Breast Cancer Metastases

Interventions Alkylating agent of physician choice registered in cancer vinflunine

Updated 7 times since 2017 Last updated: Aug 9, 2019 Started: Jul 31, 2009 Primary completion: Aug 27, 2012 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01091168, this PHASE3 trial focuses on Breast Cancer and Metastases and remains completed. Sponsored by Pierre Fabre Medicament, it has been updated 7 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Oct 2019 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pierre Fabre Medicament

Data source: Pierre Fabre Medicament

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Ancona, Italy , Angers, France , Arkhangelsk, Russia , Aviano, Italy , Barcelona, Spain , Berlin, Germany , Bolzano, Italy , Brest, France , Brindisi, Italy and 70 more locations